北美癫痫市场预测至 2030 年 - 区域分析 - 按类型（进行性肌阵挛性癫痫、反射性癫痫、全身性癫痫等）、给药途径（口服、肠胃外等）、治疗类型（第一代药物、第二代药物和第三代药物）、年龄组（成人和儿童）和分销渠道（医院药房、零售药房等）

Historic Data: 2020-2021   |   Base Year: 2022   |   Forecast Period: 2023-2030

No. of Pages: 135    |    Report Code: BMIRE00030781    |    Category: Life Sciences

Available Report Formats

pdf-format excel-format pptx-format
Request Free Sample Buy Now
North America Epilepsy Market
Free Sample Buy Now
2022 年北美癫痫市场价值为 25.771 亿美元，预计到 2030 年将达到 36.0934 亿美元；预计 2022 年至 2030 年的复合年增长率为 4.3%。

癫痫患病率上升推动北美癫痫市场发展

癫痫，也称为癫痫症，是一种慢性脑部疾病。其特征是反复发作，即身体某一部位或整个身体短暂不自主运动。癫痫发作会改变感觉、行为、意识和肌肉运动。癫痫可能是由于遗传性疾病或后天性脑损伤（如创伤或中风）引起的。根据世界卫生组织 (WHO) 2023 年 2 月发布的数据，癫痫占全球疾病负担的很大一部分，影响着全球近 5000 万人。此外，估计每 1,000 人中有 4-10 人患有活动性癫痫（即需要治疗或持续癫痫发作）。每年有近 500 万人被诊断出患有癫痫。高收入国家估计每年每 100,000 人中有 49 人报告患有癫痫。在低收入和中等收入国家，这一数字可能高达每 100,000 人中有 139 人。癫痫发病率的上升可归因于道路交通伤害和出生相关伤害数量的增加，以及脑囊虫病或疟疾等地方性疾病的风险增加。世卫组织还指出，大约 70% 的癫痫患者可以通过使用药物摆脱癫痫发作。控制癫痫的治疗方法包括抗癫痫药物、特殊饮食（除抗癫痫药物外）和手术；然而，抗癫痫药物治疗是大多数患者的主要治疗方法。因此，全球癫痫患病率的上升推动了市场的增长。

北美癫痫市场概述

北美癫痫市场分为美国、加拿大和墨西哥。该地区的市场增长归因于癫痫患者人数的增加、人口老龄化的增长、该地区癫痫药物领域的持续研发、新产品的监管批准增加以及癫痫药物事故和脑损伤数量的增加。

北美癫痫市场收入及预测至 2030 年（百万美元）

北美癫痫市场细分

北美癫痫市场分为类型、给药途径、治疗类型、年龄组、分销渠道和国家。

根据类型，北美癫痫市场分为进行性肌阵挛性癫痫、反射性癫痫、全身性癫痫和其他。全身性癫痫部分在 2022 年占据最大市场份额。

就给药途径而言，北美癫痫市场分为口服、肠外和其他。口服部分在 2022 年占据最大市场份额。

按治疗类型，北美癫痫市场分为第一代药物、第二代药物和第三代药物。第三代药物细分市场在 2022 年占据了最大的市场份额。

根据年龄组，北美癫痫市场分为成人和儿童。成人细分市场在 2022 年占据了更大的市场份额。

就分销渠道而言，北美癫痫市场分为医院药房、零售药房和其他。医院药房细分市场在 2022 年占据了最大的市场份额。

按国家/地区划分，北美癫痫市场分为美国、加拿大和墨西哥。2022 年，美国占据了北美癫痫市场份额的主导地位。

雅培实验室、辉瑞公司、卫材株式会社、UCB SA、LivaNova Plc、诺华公司、美敦力公司、葛兰素史克公司和 H. Lundbeck AS 是北美癫痫市场的一些领先公司。

North America Epilepsy Strategic Insights

Strategic insights for North America Epilepsy involve closely monitoring industry trends, consumer behaviours, and competitor actions to identify opportunities for growth. By leveraging data analytics, businesses can anticipate market shifts and make informed decisions that align with evolving customer needs. Understanding these dynamics helps companies adjust their strategies proactively, enhance customer engagement, and strengthen their competitive edge. Building strong relationships with stakeholders and staying agile in response to changes ensures long-term success in any market.

strategic-framework/north-america-epilepsy-market-strategic-framework.webp
Get more information on this report

North America Epilepsy Report Scope

Report Attribute Details
Market size in 2022 US$ 2,577.10 Million
Market Size by 2030 US$ 3,609.34 Million
Global CAGR (2022 - 2030) 4.3%
Historical Data 2020-2021
Forecast period 2023-2030
Segments Covered By 类型
  • 进行性肌阵挛性癫痫
  • 反射性癫痫
  • 全身性癫痫
By 给药途径
  • 口服
  • 肠胃外
By 年龄组
  • 成人和儿童
Regions and Countries Covered 北美
  • 美国
  • 加拿大
  • 墨西哥
Market leaders and key company profiles
  • Abbott Laboratories
  • Pfizer Inc
  • Eisai Co Ltd
  • UCB SA
  • LivaNova Plc
  • Novartis AG
  • Medtronic Plc
  • GSK Plc
  • H. Lundbeck AS
    		•
    Get more information on this report

    North America Epilepsy Regional Insights

    The regional scope of North America Epilepsy refers to the geographical area in which a business operates and competes. Understanding regional nuances, such as local consumer preferences, economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved regions or adapting their offerings to meet regional demands. A clear regional focus allows for more effective resource allocation, targeted marketing, and better positioning against local competitors, ultimately driving growth in those specific areas.

    geography/north-america-epilepsy-market-geography.webp
    Get more information on this report
    Identical Market Reports with other Region/Countries

    The List of Companies - North America Epilepsy Market

    1. Abbott Laboratories
    2. Pfizer Inc
    3. Eisai Co Ltd
    4. UCB SA
    5. LivaNova Plc
    6. Novartis AG
    7. Medtronic Plc
    8. GSK Plc
    9. H. Lundbeck AS
    Frequently Asked Questions
    How big is the North America Epilepsy Market?

    The North America Epilepsy Market is valued at US$ 2,577.10 Million in 2022, it is projected to reach US$ 3,609.34 Million by 2030.

    What is the CAGR for North America Epilepsy Market by (2022 - 2030)?

    As per our report North America Epilepsy Market, the market size is valued at US$ 2,577.10 Million in 2022, projecting it to reach US$ 3,609.34 Million by 2030. This translates to a CAGR of approximately 4.3% during the forecast period.

    What segments are covered in this report?

    The North America Epilepsy Market report typically cover these key segments-

  • 类型 (进行性肌阵挛性癫痫, 反射性癫痫, 全身性癫痫)
  • 给药途径 (口服, 肠胃外)
  • 年龄组 (成人和儿童)

    • What is the historic period, base year, and forecast period taken for North America Epilepsy Market?

    The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the North America Epilepsy Market report:

  • Historic Period : 2020-2021
  • Base Year : 2022
  • Forecast Period : 2023-2030
    • Who are the major players in North America Epilepsy Market?

    The North America Epilepsy Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:

  • Abbott Laboratories
  • Pfizer Inc
  • Eisai Co Ltd
  • UCB SA
  • LivaNova Plc
  • Novartis AG
  • Medtronic Plc
  • GSK Plc
  • H. Lundbeck AS
    • Who should buy this report?

    The North America Epilepsy Market report is valuable for diverse stakeholders, including:

    • Investors: Provides insights for investment decisions pertaining to market growth, companies, or industry insights. Helps assess market attractiveness and potential returns.
    • Industry Players: Offers competitive intelligence, market sizing, and trend analysis to inform strategic planning, product development, and sales strategies.
    • Suppliers and Manufacturers: Helps understand market demand for components, materials, and services related to concerned industry.
    • Researchers and Consultants: Provides data and analysis for academic research, consulting projects, and market studies.
    • Financial Institutions: Helps assess risks and opportunities associated with financing or investing in the concerned market.

    Essentially, anyone involved in or considering involvement in the North America Epilepsy Market value chain can benefit from the information contained in a comprehensive market report.

    north-america-epilepsy-market